Denna sida på svenska

Moustapha Hassan

Professor

Visiting address : Experimentell Cancer Medicin (ECM); Novum, plan 6, hiss F, Lab 601; Hälsovägen 7-9, 14157 Huddinge, Sweden
Postal address : Department of Laboratory Medicine (LABMED), H5, Clinical research center, Experimentell Cancer Medicin (ECM); Novum, plan 6, hiss F, Lab 601; Hälsovägen 7-9, 14157 Huddinge, Sweden
Delivery address : KFC, ECM, Novum plan 6, Lab 601; Karolinska Universitetssjukhuset Huddinge; Vårdarvägen 1, 14152 Huddinge, Sweden

Publications

Commentary: Impact of a deletion of the full-length and short isoform of p75NTR on cholinergic innervation and the population of postmitotic doublecortin positive cells in the dentate gyrus
Sabry Ma, Fares M, Folkesson R, Al-ramadan M, Alabkal J, Al-kafaji G, et al
Frontiers in neuroanatomy 2016;10():14-

Development and biodistribution of a theranostic aluminum phthalocyanine nanophotosensitizer
Asem H, El-fattah Aa, Nafee N, Zhao Y, Khalil L, Muhammed M, et al
Photodiagnosis and photodynamic therapy 2016;13():48-57

Complement activation is involved in the hepatic injury caused by high-dose exposure of mice to perfluorooctanoic acid
Botelho Sc, Saghafian M, Pavlova S, Hassan M, Depierre Jw, Abedi-valugerdi M
Chemosphere 2015;129():225-31

Cytochrome P450 2J2, a new key enzyme in cyclophosphamide bioactivation and a potential biomarker for hematological malignancies
El-serafi I, Fares M, Abedi-valugerdi M, Afsharian P, Moshfegh A, Terelius Y, et al
The pharmacogenomics journal 2015;15(5):405-13

Cytochrome P450 Oxidoreductase Influences CYP2B6 Activity in Cyclophosphamide Bioactivation
El-serafi I, Afsharian P, Moshfegh A, Hassan M, Terelius Y
PloS one 2015;10(11):e0141979-

DNA damage, lysosomal degradation and Bcl-xL deamidation in doxycycline- and minocycline-induced cell death in the K562 leukemic cell line
Fares M, Abedi-valugerdi M, Hassan M, Potácová Z
Biochemical and biophysical research communications 2015;463(3):268-74

Fluorescence labeled microbubbles for multimodal imaging
Barrefelt Å, Zhao Y, Larsson Mk, Egri G, Kuiper Rv, Hamm J, et al
Biochemical and biophysical research communications 2015;464(3):737-42

Immunotoxicological effects of streptozotocin and alloxan: in vitro and in vivo studies
Diab Ra, Fares M, Abedi-valugerdi M, Kumagai-braesch M, Holgersson J, Hassan M
Immunology letters 2015;163(2):193-8

The effect of circadian rhythm on pharmacokinetics and metabolism of the Cdk inhibitor, roscovitine, in tumor mice model
Sallam H, El-serafi At, Filipski E, Terelius Y, Lévi F, Hassan M
Chronobiology international 2015;32(5):608-14

Transplanted Bone Marrow-Derived Cells Contribute to Human Adipogenesis
Rydén M, Uzunel M, Hård Jl, Borgström E, Mold Je, Arner E, et al
Cell metabolism 2015;22(3):408-17

Biodegradable polymeric vesicles containing magnetic nanoparticles, quantum dots and anticancer drugs for drug delivery and imaging
Ye F, Barrefelt A, Asem H, Abedi-valugerdi M, El-serafi I, Saghafian M, et al
Biomaterials 2014;35(12):3885-94

Comparison of algorithms for oral busulphan area under the concentration-time curve limited sampling estimate
Sjöö F, El-serafi I, Enestig J, Mattsson J, Liwing J, Hassan M
Clinical drug investigation 2014;34(1):43-52

Cyclophosphamide alters the gene expression profile in patients treated with high doses prior to stem cell transplantation
El-serafi I, Abedi-valugerdi M, Potácová Z, Afsharian P, Mattsson J, Moshfegh A, et al
PloS one 2014;9(1):e86619-

DYNAMIC MR IMAGING, BIODISTRIBUTION AND PHARMACOKINETICS OF POLYMER SHELLED MICROBUBBLES CONTAINING SPION
Barrefelt A, Paradossi G, Asem H, Margheritelli S, Saghafian M, Oddo L, et al
NANO 2014;9(6):-

Hematologic malignancies in elderly patients
Hassan M, Abedi-valugerdi M
Haematologica 2014;99(7):1124-7

Posaconazole concentrations in human tissues after allogeneic stem cell transplantation
Blennow O, Eliasson E, Pettersson T, Pohanka A, Szakos A, El-serafi I, et al
Antimicrobial agents and chemotherapy 2014;58(8):4941-3

Rat islets are not rejected by anti-islet antibodies in mice treated with costimulation blockade
Diab Ra, Hassan M, Tibell A, Holgersson J, Kumagai-braesch M
Xenotransplantation 2014;21(4):353-66

Real-time assessment of tissue hypoxia in vivo with combined photoacoustics and high-frequency ultrasound
Gerling M, Zhao Y, Nania S, Norberg Kj, Verbeke Cs, Englert B, et al
Theranostics 2014;4(6):604-13

Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study
Güngör T, Teira P, Slatter M, Stussi G, Stepensky P, Moshous D, et al
Lancet (London, England) 2014;383(9915):436-48

The nanoparticulate Quillaja saponin KGI exerts anti-proliferative effects by down-regulation of cell cycle molecules in U937 and HL-60 human leukemia cells
Berenjian S, Hu K, Abedi-valugerdi M, Hassan M, Bashir Hassan S, Morein B
Leukemia & lymphoma 2014;55(7):1618-24

Activation of Wnt/β-catenin pathway in monocytes derived from chronic kidney disease patients
Al-chaqmaqchi Ha, Moshfegh A, Dadfar E, Paulsson J, Hassan M, Jacobson Sh, et al
PloS one 2013;8(7):e68937-

Biodistribution, kinetics, and biological fate of SPION microbubbles in the rat
Barrefelt Å, Saghafian M, Kuiper R, Ye F, Egri G, Klickermann M, et al
International journal of nanomedicine 2013;8():3241-54

Both sub-acute, moderate-dose and short-term, low-dose dietary exposure of mice to perfluorooctane sulfonate exacerbates concanavalin A-induced hepatitis
Qazi Mr, Hassan M, Nelson Bd, Depierre Jw, Abedi-valugerdi M
Toxicology letters 2013;217(1):67-74

Early-phase GVHD gene expression profile in target versus non-target tissues: kidney, a possible target?
Sadeghi B, Al-chaqmaqchi H, Al-hashmi S, Brodin D, Hassan Z, Abedi-valugerdi M, et al
Bone marrow transplantation 2013;48(2):284-93

Gas chromatographic-mass spectrometry method for the detection of busulphan and its metabolites in plasma and urine
El-serafi I, Terelius Y, Twelkmeyer B, Hagbjörk Al, Hassan Z, Hassan M
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2013;913-914():98-105

Increased risk of gastrointestinal acute GVHD following the addition of melphalan to busulfan/cyclophosphamide conditioning
Mårtensson T, Priftakis P, Casswall T, Ringdén O, Mattsson J, Remberger M, et al
Pediatric transplantation 2013;17(3):285-93

Multimodality imaging using SPECT/CT and MRI and ligand functionalized 99mTc-labeled magnetic microbubbles
Barrefelt Aa, Brismar Tb, Egri G, Aspelin P, Olsson A, Oddo L, et al
EJNMMI research 2013;3(1):12-

Omega-3 from fish oil augments GVHD through the enhancement of chemotherapy conditioning regimen and selective FoxP3 depletion
Al Hashmi S, Sadeghi B, Hassan Z, Abedi-valugerdi M, Lindskog M, Hassan M
Bone marrow transplantation 2013;48(6):843-8

Pharmacokinetics and biodistribution of the cyclin-dependent kinase inhibitor -CR8- in mice
Sallam H, El-serafi I, Meijer L, Hassan M
BMC pharmacology & toxicology 2013;14():50-

Role of pharmacogenetics in busulfan/cyclophosphamide conditioning therapy prior to hematopoietic stem cell transplantation
Hassan M, Andersson Bs
Pharmacogenomics 2013;14(1):75-87

Sub-acute, moderate-dose, but not short-term, low-dose dietary pre-exposure of mice to perfluorooctanoate aggravates concanavalin A-induced hepatitis
Qazi Mr, Hassan M, Nelson Bd, Depierre Jw, Abedi-valugerdi M
Toxicology letters 2013;219(1):1-7

Thermostable luciferase from Luciola cruciate for imaging of carbon nanotubes and carbon nanotubes carrying doxorubicin using in vivo imaging system
El-sayed R, Eita M, Barrefelt A, Ye F, Jain H, Fares M, et al
Nano letters 2013;13(4):1393-8

The role of programmed cell death ligand-1 (PD-L1/CD274) in the development of graft versus host disease
Al-chaqmaqchi H, Sadeghi B, Abedi-valugerdi M, Al-hashmi S, Fares M, Kuiper R, et al
PloS one 2013;8(4):e60367-

Busulphan-Cyclophosphamide Cause Endothelial Injury, Remodeling of Resistance Arteries and Enhanced Expression of Endothelial Nitric Oxide Synthase
Al-hashmi S, Boels Pjm, Zadjali F, Sadeghi B, Sallstrom J, Hultenby K, et al
PLOS ONE 2012;7(1):e30897-

DYNAMICS OF DONOR T CELL ACTIVATION DURING EARLY PHASE OF GRAFT VERSUS HOST DISEASE (GVHD): DONOR ANTIGEN PRESENTING CELLS CAN ACTIVATE ALLOGENEIC T CELLS
Sadeghi B, Al-hashmi S, Hassan Z, Hassan M
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION 2011;17(2):S345-S345

Dynamics of early histopathological changes in GVHD after busulphan/cyclophosphamide conditioning regimen
Al-hashmi S, Hassan Z, Sadeghi B, Rozell B, Hassan M
INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY 2011;4(6):596-605

Improved survival after allogeneic haematopoietic stem cell transplantation in recent years
Ringden O, Ackefors M, Berglund S, Blennow O, Dahllof G, Dlugosz A, et al
BONE MARROW TRANSPLANTATION 2011;:S167-S168

Improved Survival after Allogeneic Hematopoietic Stem Cell Transplantation in Recent Years. A Single-Center Study
Remberger M, Ackefors M, Berglund S, Blennow O, Dahllof G, Dlugosz A, et al
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION 2011;17(11):1688-97

Inhibition of proteasome deubiquitinating activity as a new cancer therapy
D'arcy P, Brnjic S, Olofsson Mh, Fryknas M, Lindsten K, De Cesare M, et al
NATURE MEDICINE 2011;17(12):1636-40

Long-term salivary function after conditioning with busulfan, fractionated or single-dose TBI
Garming-legert K, Remberger M, Ringden O, Hassan M, Dahllof G
ORAL DISEASES 2011;17(7):670-6

N-acetyl-L-cysteine increases acute graft-versus-host disease and promotes T-cell-mediated immunity in vitro
Karlsson H, Nava S, Remberger M, Hassan Z, Hassan M, Ringden O
EUROPEAN JOURNAL OF IMMUNOLOGY 2011;41(4):1143-53

Therapeutic drug monitoring is essential for intravenous busulfan therapy in pediatric hematopoietic stem cell recipients
Malar R, Sjoo F, Rentsch K, Hassan M, Gungor T
PEDIATRIC TRANSPLANTATION 2011;15(6):580-8

The Role of Pharmacokinetics and Pharmacodynamics in Early Drug Development with reference to the Cyclin-dependent Kinase (Cdk) Inhibitor - Roscovitine
Hassan M, Sallam H, Hassan Z
Sultan Qaboos University medical journal 2011;11(2):165-78

Expansion and Activation Kinetics of Immune Cells during Early Phase of GVHD in Mouse Model Based on Chemotherapy Conditioning
Sadeghi B, Al-hashmi S, Hassan Z, Rozell B, Concha H, Lundmark C, et al
CLINICAL & DEVELOPMENTAL IMMUNOLOGY 2010;:142943-

ANALYSIS, PHARMACOKINETICS AND BIODISTRIBUTION OF THE NEW CDK INHIBITOR-CR8
Sallam H, Meijer L, Hassan M
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL 2009;:235-236

CIRCADIAN VARIABILITY OF BILIRUBIN IN HEALTHY MEN DURING NORMAL SLEEP AND AFTER AN ACUTE SHIFT OF SLEEP
Larsson A, Hassan M, Ridefelt P, Axelsson J
CHRONOBIOLOGY INTERNATIONAL 2009;26(8):1613-21

DYNAMICS OF DONOR T CELL ACTIVATION DURING EARLY PHASE OF GRAFT VERSUS HOST DISEASE (GVHD): DONOR ANTIGEN PRESENTING CELLS CAN ACTIVATE ALLOGENEIC T CELLS
Sadeghi B, Al-hashmi S, Hassan Z, Lundmark C, Concha H, Rozell B, et al
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL 2009;:461-461

Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer
Amundadottir L, Kraft P, Stolzenberg-solomon Rz, Fuchs Cs, Petersen Gm, Arslan Aa, et al
NATURE GENETICS 2009;41(9):986-90

IMMUNOPATHOLOGY OF ATG PRIOR TO BONE MARROW TRANSPLANTATION IN MOUSE MODEL
Sadeghi B, Al-hashmi S, Hassan Z, Rozell B, Abedi-valugerdi M, Hassan M
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL 2009;:463-463

Liver Circadian Clock, a Pharmacologic Target of Cyclin-Dependent Kinase Inhibitor Seliciclib
Iurisci I, Filipski E, Sallam H, Harper F, Guettier C, Maire I, et al
CHRONOBIOLOGY INTERNATIONAL 2009;26(6):1169-88

N-acetyl-L-cysteine promotes T-cell mediated immunity in allogeneic settings in vivo and in vitro
Karlsson H, Nava S, Remberger M, Hassan Z, Hassan M, Ringden O
BONE MARROW TRANSPLANTATION 2009;:S51-S52

N-ACETYL-L-CYSTEINE PROMOTES T CELL MEDIATED IMMUNITY IN ALLOGENEIC SETTINGS IN VIVO AND IN VITRO
Karlsson H, Nava S, Remberger M, Hassan Z, Hassan M, Ringden O
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION 2009;15(2):127-127

THE EFFECT OF OMEGA-3 AS A DIETARY SUPPLEMENT IN A MOUSE MODEL OF STEM CELL TRANSPLANTATION (SCT)
Al-hashmi A, Sadeghi B, Hassan Z, Lindskog M, Hassan M
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL 2009;:472-472

THERAPEUTIC DRUG MONITORING IS AN IMPORTANT FACTOR DURING IV BUSULFAN TREATMENT
Malar R, Hassan M, Gungor T
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL 2009;:62-62

Age-dependent pharmacokinetics and effect of roscovitine on Cdk5 and Erk1/2 in the rat brain
Sallam H, Jimenez P, Song Hr, Vita M, Cedazo-minguez A, Hassan M
PHARMACOLOGICAL RESEARCH 2008;58(1):32-7

A prospective randomized study using N-acetyl-L-cysteine for early liver toxicity after allogeneic hematopoietic stem cell transplantation
Barkholt L, Remberger M, Hassan Z, Fransson K, Omazic B, Svahn Bm, et al
BONE MARROW TRANSPLANTATION 2008;41(9):785-90

Dynamics of fat cell turnover in humans
Spalding Kl, Arner E, Westermark Po, Bernard S, Buchholz Ba, Bergmann O, et al
NATURE 2008;453(7196):783-7

Endometrial endothelial cells are derived from donor stem cells in a bone marrow transplant recipient
Mints M, Jansson M, Sadeghi B, Westgren M, Uzunel M, Hassan M, et al
HUMAN REPRODUCTION 2008;23(1):139-43

Evaluation of immune responses to seasonal influenza vaccination in healthy volunteers and in patients after stem cell transplantation
Avetisyan G, Aschan J, Hassan M, Ljungman P
TRANSPLANTATION 2008;86(2):257-63

GVHD after chemotherapy conditioning in allogeneic transplanted mice
Sadeghi B, Aghdami N, Hassan Z, Forouzanfar M, Rozell B, Abedi-valugerdi M, et al
BONE MARROW TRANSPLANTATION 2008;42(12):807-18

Hypomethylation and apoptosis in 5-azacytidine-treated myeloid cells
Khan R, Schmidt-mende J, Karim M, Gogvadze V, Hassan M, Ekstrom Tj, et al
EXPERIMENTAL HEMATOLOGY 2008;36(2):149-57

N-&-N, a new class of cell death-inducing kinase inhibitors derived from the purine roscovitine
Bettayeb K, Sallam H, Ferandin Y, Popowycz F, Fournet G, Hassan M, et al
MOLECULAR CANCER THERAPEUTICS 2008;7(9):2713-24

Rapid and sensitive method for determination of cyclophosphamide in patients plasma samples utilizing microextraction by packed sorbent online with liquid chromatography-tandem mass spectrometry (MEPS-LC-MS/MS)
Said R, Hassan Z, Hassan M, Abdel-rehim M
JOURNAL OF LIQUID CHROMATOGRAPHY & RELATED TECHNOLOGIES 2008;31(5):683-694

Safe administration of oral BU twice daily during conditioning for stem cell transplantation in a paediatric population: A comparative study between the standard 4-dose and a 2-dose regimen
Mellgren K, Nilsson C, Fasth A, Abrahamsson J, Winiarski J, Ringden O, et al
BONE MARROW TRANSPLANTATION 2008;41(7):621-5

The effect of administration order of BU and CY on engraftment and toxicity in HSCT mouse model
Sadeghi B, Jansson M, Hassan Z, Mints M, Hagglund H, Abedi-valugerdi M, et al
BONE MARROW TRANSPLANTATION 2008;41(10):895-904

Chimerism of dendriticand regulatory T-cells after chemotherapy based conditioning in GVHD mouse model
Sadeghi B, Hassan Z, Abedi Valugerdi M, Hassan M
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL 2007;:220-220

Effect of busulphan dose adjustment on regimen-related toxicity
Hassan Z, Remberger M, Ringden O, Oberg G, Bekassy A, Hassan M
BONE MARROW TRANSPLANTATION 2007;:S48-S48

HER-2/NEU mRNA in peripheral blood & bone marrow in female breast cancer patients
El Hamid Aa, Elkamash M, Eskander G, Hassan A, Aziz Fa, Attia F, et al
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL 2007;:537-538

Higher plasma but not intracellular concentrations after infusion with liposomal daunorubicin compared with conventional daunorubicin in adult acute myeloid leukemia
Lofgren C, Lehmann S, Jonsson-videsater K, Mollgard L, Linder O, Tidefelt U, et al
THERAPEUTIC DRUG MONITORING 2007;29(5):626-31

Hypomethylation and apoptosis in 5-azacytidine treated myeloid cells
Khan R, Schmidt-mende J, Karimi M, Forsblom Am, Gogvadze V, Hassan M, et al
LEUKEMIA RESEARCH 2007;:S62-S63

Mice model of graft-versus-host disease based on chemotherapy conditioning
Sadeghi B, Hassan Z, Valugerdi Ma, Hassan M
BONE MARROW TRANSPLANTATION 2007;:S112-S112

Simultaneous determination of busulphan in plasma samples by liquid chromatography-electrospray ionization mass spectrometry utilizing microextraction in packed syringe (MEPS) as on-line sample preparation method
Abdel-rehim M, Hassan Z, Skansem P, Hassan M
JOURNAL OF LIQUID CHROMATOGRAPHY & RELATED TECHNOLOGIES 2007;30(20):3029-3041

The effect of repeated administration of cyclophosphamide on cytochrome P4502B in rats
Afsharian P, Ylva Tz, Hassan Z, Nilsson C, Lundgren S, Hassan M
CLINICAL CANCER RESEARCH 2007;13(14):4218-24

The role of human CYP2B6 polymorphism in the bioactivation of cyclophosphamide using CDNA expressed enzymes
Afsharian P, Teredius Y, Hidestrand M, Ingelman-sundberg M, Hassan M, Lundgren S
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION 2007;13(2):70-71

CMV-specific T-cell immunity after allogeneic SCT
Avetisyan G, Larsson K, Nilsson C, Hassan M, Ljungman P
BONE MARROW TRANSPLANTATION 2006;:S172-S172

Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1
Ott Mg, Schmidt M, Schwarzwaelder K, Stein S, Siler U, Koehl U, et al
NATURE MEDICINE 2006;12(4):401-9

Effect of busulphan dose adjustment on regimen-related toxicity.
Hassan Z, Remberger M, Ringden O, Oberg G, Bekassy An, Hassan M
BLOOD 2006;108(11):97A-97A

Impact on the cytomegalovirus (CMV) viral load by CMV-specific T-cell immunity in recipients of allogeneic stem cell transplantation
Avetisyan G, Larsson K, Aschan J, Nilsson C, Hassan M, Ljungman P
BONE MARROW TRANSPLANTATION 2006;38(10):687-92

Inhibitory effect of 5-fluorouracil on cytochrome P4502C9 activity in cancer patients
Gunes A, Coskun U, Boruban C, Gunel N, Babaoglu Mo, Sencan O, et al
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY 2006;98(2):197-200

Myeloablative and immunosuppressive properties of treosulfan in mice
Sjoo F, Hassan Z, Abedi-valugerdi M, Griskevicius L, Nilsson C, Remberger M, et al
EXPERIMENTAL HEMATOLOGY 2006;34(1):115-21

Pharmacodynamic study of 5-azacytidine in the P39 cell line
Khan R, Aggerholm A, Hokland P, Hassan M, Hellstrom-lindberg E
EXPERIMENTAL HEMATOLOGY 2006;34(1):35-43

Pharmacogenetics of cyclophosphamide in patients with hematological malignancies
Xie Hj, Griskevicius L, Stahle L, Hassan Z, Yasar U, Rane A, et al
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES 2006;27(1):54-61

Safe administration of oral busulphan b.i.d during conditioning for stem cell transplantation in a paediatric population - a comparative study between the standard 4-dose regimen and a 2-dose regimen
Mellgren K, Nilsson C, Fasth A, Abrahamsson J, Soderhall S, Winiarski J, et al
BONE MARROW TRANSPLANTATION 2006;:S204-S204

Bacterial lipopolysaccharide both renders resistant mice susceptible to mercury-induced autoimmunity and exacerbates such autoimmunity in susceptible mice
Abedi-valugerdi M, Nilsson C, Zargari A, Gharibdoost F, Depierre Jw, Hassan M
CLINICAL AND EXPERIMENTAL IMMUNOLOGY 2005;141(2):238-47

Cell-mediated immune responses to influenza vaccination in healthy volunteers and allogeneic stem cell transplant recipients
Avetisyan G, Ragnavolgyi E, Toth Gt, Hassan M, Ljungman P
BONE MARROW TRANSPLANTATION 2005;36(5):411-5

Cyclophosphamide induces mRNA, protein and enzyme activity of cytochrome P450 in rat
Xie H, Afsharian P, Terelius Y, Mirghani Ra, Yasar U, Hagbjork Al, et al
XENOBIOTICA 2005;35(3):239-51

Development and validation of a liquid chromatography and tandem mass spectrometry method for determination of roscovitine in plasma and urine samples utilizing on-line sample preparation
Vita M, Skansen P, Hassan M, Abdel-rehim M
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES 2005;817(2):303-7

Effect of altering administration order of busulphan and cyclophosphamide on the myeloablative and immunosuppressive properties of the conditioning regimen in mice
Nilsson C, Forsman J, Hassan Z, Abedi-valugerdi M, O'connor C, Concha H, et al
EXPERIMENTAL HEMATOLOGY 2005;33(3):380-7

Exposure to mercuric chloride during the induction phase and after the onset of collagen-induced arthritis enhances immune/autoimmune responses and exacerbates the disease in DBA/1 mice
Hansson M, Djerbi M, Rabbani H, Mellstedt H, Gharibdoost F, Hassan M, et al
IMMUNOLOGY 2005;114(3):428-37

Fetal mesenchymal stem-cell engraftment in bone after in utero transplantation in a patient with severe osteogenesis imperfecta
Le Blanc K, Gotherstrom C, Ringden O, Hassan M, Mcmahon R, Horwitz E, et al
TRANSPLANTATION 2005;79(11):1607-14

Investigating cyclin B1 positive subpopulation in Mantle cell lymphoma using FICTION on paraffin embedded tissue
Emanuelsson Ek, Jansson M, Fahlstrom G, Hassan M, Sander B
CHROMOSOME RESEARCH 2005;:180-180

Long-term follow-up of patients treated by gene therapy for X-linked chronic granulomatous disease.
Ott Mg, Grez M, Stein S, Siler U, Koehl U, Kuehlcke K, et al
BLOOD 2005;106(11):60A-60A

Microextraction in packed syringe/liquid chromatography/electrospray tandem mass spectrometry for quantification of olomoucine in human plasma samples
Abdel-rehim M, Skansen P, Vita M, Hassan Z, Blomberg L, Hassan M
ANALYTICA CHIMICA ACTA 2005;539(1-2):35-39

Stability, pKa and plasma protein binding of roscovitine
Vita M, Abdel-rehim M, Nilsson C, Hassan Z, Skansen P, Wan H, et al
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES 2005;821(1):75-80

The effect ciprofloxacin on cyclophosphamide pharmacokinetics in patients with non-Hodgkin lymphoma
Afsharian P, Xie H, Hassan M
BONE MARROW TRANSPLANTATION 2005;:S239-S240

The effect of ciprofloxacin on cyclophosphamide pharmacokinetics in patients with non-Hodgkin lymphoma
Afsharian P, Mollgard L, Hassan Z, Xie Hj, Kimby E, Hassan M
EUROPEAN JOURNAL OF HAEMATOLOGY 2005;75(3):206-11

The effect of repeated administration of cyclophosphamide on CYP2B1 and 2B2 in rat.
Afsharian P, Terelius Y, Lundgren S, Hassan M
BLOOD 2005;106(11):193B-193B

The influence of administration order of busulphan and cyclophosphamide on dendritic cells in stem cell transplantation mouse model
Nilsson C, Forsman J, Cussen E, Hassan Z, Abedi-valugerdi Ma, Concha H, et al
BONE MARROW TRANSPLANTATION 2005;:S140-S140

Tissue distribution, pharmacokinetics and identification of roscovitine metabolites in rat
Vita M, Abdel-rehim M, Olofsson S, Hassan Z, Meurling L, Siden A, et al
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES 2005;25(1):91-103

Analysis of roscovitine using novel high performance liquid chromatography and UV-detection method: pharmacokinetics of roscovitine in rat
Vita M, Meurling L, Pettersson T, Cruz-siden M, Siden A, Hassan M
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS 2004;34(2):425-31

Evaluation of existing limited sampling models for therapeutic drug monitoring of busulphan in children and adults undergoing SCT.
Hassan Z, Sandstrom M, Hassan M
BLOOD 2004;104(11):326A-326A

Gene therapy for x-linked chronic granulomatous disease
Ott Mg, Stein S, Koehl U, Schilz A, Kuhlcke K, Schmidt M, et al
BLOOD 2004;104(11):120A-120A

Lung epithelial cells and type II pneumocytes of donor origin after allogeneic hematopoietic stem cell transplantation
Mattson J, Jansson M, Wernerson A, Hassan M
TRANSPLANTATION 2004;78(1):154-7

Mesenchymal stem cell engraftment in bone following in utero transplantation in a patient with severe osteogenesis imperfecta.
Le Blanc K, Gotherstrom C, Ringden O, Hassan M, Mcmahon R, Horwitz E, et al
BLOOD 2004;104(11):147A-147A

Quantitative pharmacogenetics of cyclophosphamide in patients with hematological malignancies.
Hassan M, Xie Hj, Stahle L, Hassan Z, Kimby E
BLOOD 2004;104(11):235B-235B

The effect of administration order of busulphan and cyclophosphamide on the myeloblative and immunosuppressive properties of the conditioning regimen
Nilsson C, Forsman J, O'connor C, Concha H, Hassan M
BONE MARROW TRANSPLANTATION 2004;:S308-S308

Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells
Le Blanc K, Rasmusson I, Sundberg B, Gotherstrom C, Hassan M, Uzunel M, et al
LANCET 2004;363(9419):1439-41

Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells
Le Blanc K, Rasmusson I, Sundberg B, Gotherstrom C, Hassan M, Uzunel M, et al
BONE MARROW TRANSPLANTATION 2004;:S185-S185

Alteration of pharmacokinetics of cyclophosphamide and suppression of the cytochrome P450 genes by ciprofloxacin
Xie Hj, Griskevicius L, Broberg U, Lundgren S, Carlens S, Meurling L, et al
BONE MARROW TRANSPLANTATION 2003;31(3):197-203

Bioactivation of cyclophosphamide: the role of polymorphic CYP2C enzymes
Griskevicius L, Yasar U, Sandberg M, Hidestrand M, Eliasson E, Tybring G, et al
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY 2003;59(2):103-9

Correlation between busulphan concentration and transplantation related toxicity in patients undergoing SCT.
Hassan M, Aschan J, Hassan Z, Ringden O, Winiarski J, Ljungman P, et al
BLOOD 2003;102(11):707A-707A

Fractionated TBI correlates with less T cell mixed chimerism but increased risk of relapse compared to busulphan in patients with haematological malignancies after allogeneic stem cell transplantation
Mattsson J, Uzunel M, Remberger M, Hassan M
BONE MARROW TRANSPLANTATION 2003;32(5):477-83

Immunization of colorectal carcinoma patients with a recombinant Canarypox virus expressing the tumor antigen Ep-CAM/KSA (ALVAC-KSA) and granulocyte macrophage colonystimulating factor induced a tumor-specific cellular immune response
Ullenhag Gj, Frodin Je, Mosolits S, Kiaii S, Hassan M, Bonnet Mc, et al
CLINICAL CANCER RESEARCH 2003;9(7):2447-56

Inhibitory effect of 5-fluorouracil on CYP2C9 activity
Gunes A, Coskun U, Gunel N, Bozkurt A, Rane A, Hassan M, et al
DRUG METABOLISM REVIEWS 2003;:37-37

N-acetyl-L-cysteine does not affect the pharmacokinetics or myelosuppressive effect of busulfan during conditioning prior to allogeneic stem cell transplantation
Sjoo F, Aschan J, Barkholt L, Hassan Z, Ringden O, Hassan M
BONE MARROW TRANSPLANTATION 2003;32(4):349-54

On-line derivatization utilizing solid-phase microextraction (SPME) for determination of busulphan in plasma using gas chromatography-mass spectrometry (GC-MS)
Abdel-rehim M, Hassan Z, Blomberg L, Hassan M
THERAPEUTIC DRUG MONITORING 2003;25(3):400-6

Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation
Xie Hj, Yasar U, Lundgren S, Griskevicius L, Terelius Y, Hassan M, et al
PHARMACOGENOMICS JOURNAL 2003;3(1):53-61

Role of polyphorphic human CYP2B6 in cyclophosphamide bioactivation
Xie Hj, Yasar U, Lundgren S, Griskevicius L, Terelius Y, Hassan M, et al
DRUG METABOLISM REVIEWS 2003;:129-129

The effect of metronidazole on busulfan pharmacokinetics in patients undergoing hematopoietic stem cell transplantation
Nilsson C, Aschan J, Hentschke P, Ringden O, Ljungman P, Hassan M
BONE MARROW TRANSPLANTATION 2003;31(6):429-35

A phase II trial of liposomal busulphan as an intravenous myeloablative agent prior to stem cell transplantation: 500 mg/m(2) as a optimal total dose for conditioning
Hassan M, Nilsson C, Hassan Z, Gungor T, Aschan J, Winiarski J, et al
BONE MARROW TRANSPLANTATION 2002;30(12):833-41

Effect of cyclophosphamide on gene expression of cytochromes P450 and beta-actin in the HL-60 cell line
Xie Hj, Lundgren S, Broberg U, Finnstrom N, Rane A, Hassan M
EUROPEAN JOURNAL OF PHARMACOLOGY 2002;449(3):197-205

Simple method based on fluorescent detection for the determination of 4-hydroxycyclophosphamide in plasma
Griskevicius L, Meurling L, Hassan M
THERAPEUTIC DRUG MONITORING 2002;24(3):405-9

The effect of modulation of glutathione cellular content on busulphan-induced cytotoxicity on hematopoietic cells in vitro and in vivo
Hassan Z, Hellstrom-lindberg E, Alsadi S, Edgren M, Hagglund H, Hassan M
BONE MARROW TRANSPLANTATION 2002;30(3):141-7

Alteration of interleukin 2 (IL-2) pharmacokinetics and function by IL-2 antibodies induced after treatment of colorectal carcinoma patients with a combination of monoclonal antibody 17-1A, granulocyte macrophage colony-stimulating factor, and IL-2
Skog Alh, Wadhwa M, Hassan M, Gharizadeh B, Bird C, Ragnhammar P, et al
CLINICAL CANCER RESEARCH 2001;7(5):1163-70

Bioavailability and dose-dependent anti-tumour effects of 9-cis retinoic acid on human neuroblastoma xenografts in rat
Ponthan F, Kogner P, Bjellerup P, Klevenvall L, Hassan M
BRITISH JOURNAL OF CANCER 2001;85(12):2004-9

Evidence that the major oxysterols in human circulation originate from distinct pools of cholesterol: a stable isotope study
Meaney S, Hassan M, Sakinis A, Lutjohann D, Von Bergmann K, Wennmalm A, et al
JOURNAL OF LIPID RESEARCH 2001;42(1):70-8

Pharmacokinetics of liposomal busulphan in man
Hassan Z, Ljungman P, Ringden O, Winiarski J, Nilsson C, Aschan J, et al
BONE MARROW TRANSPLANTATION 2001;27(5):479-85

Population pharmacokinetic analysis resulting in a tool for dose individualization of busulphan in bone marrow transplantation recipients
Sandstrom M, Karlsson Mo, Ljungman P, Hassan Z, Jonsson En, Nilsson C, et al
BONE MARROW TRANSPLANTATION 2001;28(7):657-64

The meyloablative and immunosuppressive properties of treosulfan in mice.
Griskevicius L, Gaughan U, Canaparo R, Nilsson C, Hassan M
BLOOD 2001;98(11):316B-316B

The pharmacodynamic effect of busulfan in the P39 myeloid cell line in vitro
Hassan Z, Hassan M, Hellstrom-lindberg E
LEUKEMIA 2001;15(8):1240-7

The vitamin A analogues: 13-cis retinoic acid, 9-cis retinoic acid, and Ro 13-6307 inhibit neuroblastoma tumour growth in vivo
Ponthan F, Borgstrom P, Hassan M, Wassberg E, Redfern Cpf, Kogner P
MEDICAL AND PEDIATRIC ONCOLOGY 2001;36(1):127-31

Amifostins (ethyol) effect on the cytotoxicity of Ara-C and daunorubicin in the promyelocytic leukemia cell-line HL-60 and its doxorubicin resistant subline HL-60R.
Broberg U, Hassan M, Paul C
BLOOD 2000;96(11):178B-178B

A phase I/II study of multiple-dose intravenous busulfan as myeloablation prior to stem cell transplantation
Olavarria E, Hassan M, Eades A, Nilsson C, Timms A, Matthews J, et al
LEUKEMIA 2000;14(11):1954-9

Capillary gas chromatography of trichlorophenols using ammonia as carrier gas
Abdel-rehim M, Hassan M
HRC-JOURNAL OF HIGH RESOLUTION CHROMATOGRAPHY 2000;23(2):156-157

Ketobemidone may alter busulfan pharmacokinetics during high-dose therapy
Hassan M, Svensson Jo, Nilsson C, Hentschke P, Al-shurbaji A, Aschan J, et al
THERAPEUTIC DRUG MONITORING 2000;22(4):383-5

Pharmacokinetics of liposomal busulfan in man.
Hassan Z, Ljungman P, Ringden O, Winiarski J, Nilsson C, Aschan J, et al
BLOOD 2000;96(11):387A-387A

Phase I clinical trial of liposomal busulphan.
Hassan M, Nilsson C, Ljungman P, Hassau Z, Ringden O, Hentschke P, et al
BLOOD 2000;96(11):388A-388A

The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence on therapeutic efficacy and therapy-related toxicity
Hassan M, Ljungman P, Ringden O, Hassan Z, Oberg G, Nilsson C, et al
BONE MARROW TRANSPLANTATION 2000;25(9):915-24

A mechanism-based pharmacokinetic-enzyme model for cyclophosphamide autoinduction in breast cancer patients
Hassan M, Svensson Ush, Ljungman P, Bjorkstrand B, Olsson H, Bielenstein M, et al
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY 1999;48(5):669-77

Biodistribution of liposomal I-131-VIP in rat using gamma camera
Refai E, Jonsson C, Andersson M, Jacobsson H, Larsson S, Kogner P, et al
NUCLEAR MEDICINE AND BIOLOGY 1999;26(8):931-6

Busulfan-induced G2 arrest and apoptosis in P39 myeloid cell
Hassan Z, Hassan M, Hellstrom-lindberg E
BLOOD 1999;94(10):192B-192B

In vivo dynamic distribution of I-131-glucagon-like peptide-1 (7-36) amide in the rat studied by gamma camera
Hassan M, Eskilsson A, Nilsson C, Jonsson C, Jacobsson H, Refai E, et al
NUCLEAR MEDICINE AND BIOLOGY 1999;26(4):413-20

In vivo evaluation of the biodistribution of C-11-labeled PD153035 in rats without and with neuroblastoma implants
Fredriksson A, Johnstrom P, Thorell Jo, Von Heijne G, Hassan M, Eksborg S, et al
LIFE SCIENCES 1999;65(2):165-74

Liposomal busulphan - Pharmacokinetics in mouse, rat and man.
Hassan M, Ljungman P, Ringden O, Hassan Z, Nilsson C
BONE MARROW TRANSPLANTATION 1999;:S73-S73

Pharmacokinetics of cyclophosphamide and its 4-hydroxy cyclophosphamide in breast cancer patients: A pharmacokinetic model involving enzyme induction.
Hassan M, Ljungman P, Svensson U, Bjorkstrand B, Nilsson C, Karlsson M
BONE MARROW TRANSPLANTATION 1999;:S40-S40

The influence of interferon-alpha on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite in patients with multiple myeloma
Hassan M, Nilsson C, Olsson H, Lundin J, Osterborg A
EUROPEAN JOURNAL OF HAEMATOLOGY 1999;63(3):163-70

The pharmacokinetics of low dose of liposomal busulphan in man.
Hassan M, Ljungman P, Ringden O, Hassan Z, Nilsson C
BLOOD 1999;94(10):150A-150A

The role of busulfan in bone marrow transplantation
Hassan M
MEDICAL ONCOLOGY 1999;16(3):166-76

The somatostatin analogue octreotide inhibits neuroblastoma growth in vivo
Borgstrom P, Hassan M, Wassberg E, Refai E, Jonsson C, Larsson Sa, et al
PEDIATRIC RESEARCH 1999;46(3):328-32

Liposomal busulphan: bioavailability and effect on bone marrow in mice
Hassan Z, Nilsson C, Hassan M
BONE MARROW TRANSPLANTATION 1998;22(9):913-8

Pharmacokinetics and distribution of liposomal busulfan in the rat: a new formulation for intravenous administration
Hassan M, Hassan Z, Nilsson C, Rehim Ma, Kumlien S, Elfsson B, et al
CANCER CHEMOTHERAPY AND PHARMACOLOGY 1998;42(6):471-8

The influence of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: Timing interval effect on therapeutic efficacy and drug related toxicity.
Hassan M, Ljungman P, Ringden O, Hassan Z, Oberg G, Bekassy A
BLOOD 1998;92(10):684A-684A

The influence of interferon-alpha on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite in myeloma patients.
Hassan M, Olsson H, Lundin J, Nilsson C, Osterborg A
BLOOD 1998;92(10):277B-277B

The relationship between hepatic veno-occlusive disease (VOD) and busulphan concentrations
Hassan M, Oberg G, Ljungman P, Bekassy Am, Ringden O
BRITISH JOURNAL OF HAEMATOLOGY 1998;102(1):152-152

A new formulation of busulphan for intravenous administration: Pharmacokinetics and organ distribution.
Hassan M, Syruckova Z, Ljungman P, Ehrsson H, Kallberg N
BLOOD 1997;90(10):1621-1621

Correlation between hepatic veno-occlusive disease (VOD) and busulphan levels using limited sampling model for dose estimation.
Hassan M, Oberg G, Ljungman P, Sandstrom M, Bekassy A, Karlsson M, et al
BLOOD 1997;90(10):1106-1106

High busulfan concentrations are associated with increased transplant-related mortality in allogeneic bone marrow transplant patients
Ljungman P, Hassan M, Bekassy An, Ringden O, Oberg G
BONE MARROW TRANSPLANTATION 1997;20(11):909-13

Somatostatin in neuroblastoma and ganglioneuroma
Kogner P, Borgstrom P, Bjellerup P, Schilling Fh, Refai E, Jonsson C, et al
EUROPEAN JOURNAL OF CANCER 1997;33(12):2084-9

Aspects concerning busulfan pharmacokinetics and bioavailability
Hassan M, Ehrsson H, Ljungman P
LEUKEMIA & LYMPHOMA 1996;22(5-6):395-407

Busulphan kinetics and limited sampling model in children with leukemia and inherited disorders
Hassan M, Fasth A, Gerritsen B, Haraldsson A, Syruckova Z, Vandenberg H, et al
BONE MARROW TRANSPLANTATION 1996;18(5):843-50

Enantiomer separation of underivatized tocainide and related compounds by CGC using ammonia as carrier gas
Abdelrehim M, Karlen A, Zhang L, Kamel M, Hassan M
JOURNAL OF MICROCOLUMN SEPARATIONS 1996;8(2):151-156

Infection-associated hemophagocytic syndrome complicated by infectious lymphoproliferation: A case report
Syruckova Z, Stary J, Sedlacek P, Smisek P, Vavrinec J, Komrska V, et al
PEDIATRIC HEMATOLOGY AND ONCOLOGY 1996;13(2):143-50

Influence of busulphan concentrations on long-term survival in autologous and allogeneic bone marrow transplant patients
Ljungman P, Hassan M, Bekassy An, Ringden O, Oberg G
BRITISH JOURNAL OF HAEMATOLOGY 1996;:959-959

The influence of busulphan on cyclophosphamide pharmacokinetics in bone marrow transplantation
Hassan M, Ljungman P, Oberg G, Ringden O, Syruckova Z, Bekassy A, et al
BRITISH JOURNAL OF HAEMATOLOGY 1996;:953-953

BUSULFAN CONCENTRATION IN RELATION TO PERMANENT ALOPECIA IN RECIPIENTS OF BONE-MARROW TRANSPLANTS
Ljungman P, Hassan M, Bekassy An, Ringden O, Oberg G
BONE MARROW TRANSPLANTATION 1995;15(6):869-71

Effect of ammonia on the response of the electron capture detector (ECD)
Abdelrehim M, Kamel M, Hassan M
HRC-JOURNAL OF HIGH RESOLUTION CHROMATOGRAPHY 1995;18(12):757-759

KINETICS AND METABOLISM OF 2-CHLORO-2'-DEOXYADENOSINE AND 2-CHLORO-2'-ARABINO-FLUORO-2'-DEOXYADENOSINE IN THE ISOLATED-PERFUSED RAT-LIVER
Albertioni F, Hassan M, Silberring J, Liliemark J
EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS 1995;20(3):225-32

One year on tacrine (THA): clinical and biochemical effects in patients with dementia of the Alzheimer type
Ahlin A, Junthé T, Hassan M, Nybäck H
International psychogeriatrics 1995;7(1):75-83

Show all publications